Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3181)	6/3/1999 12:14:00 PM
From: Don Miller	Respond to of 10280

Thank you, this three board review stuff is getting old.

To: Biomaven who wrote (3181)	6/3/1999 3:40:00 PM
From: Vector1	Read Replies (3) \| Respond to of 10280

<<3.FDA letters-very common.Start high and come down.Very common but ususaly not published on wires. >> The shorts are after SEPR big time. No big deal but will cause substantial price swings. ML also came out with a positive report today. If Xen has the same (or better) effacacy as Albuterol but a lower incidence of side effects it should eventually dominate the market. Has SEPR done any deals with company's like Inhale or Dura that have metered dose inhaler technology. V1